Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Strides Arcolab is currently trading at Rs 649.00, up by 16.70 points or 2.64% from its previous closing of Rs 632.65 on the BSE.
The scrip opened at Rs 636.05 and has touched a new high of Rs 653.00 and low of Rs 636.00. So far 34690 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 10 has touched a new 52 week high of Rs 653.00 on 19-Apr-2012 and a 52 week low of Rs 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs 653.00 and Rs 617.60 respectively. The current market cap of the company is Rs. 3769.99 crore.
The promoters holding in the company stood at 28.35% while Institutions and Non-Institutions held 55.55% and 16.11% respectively.
Strides Arcolab’s wholly owned subsidiary - Onco Therapies, has received USFDA approvals for Cisplatin Injection, 1 mg/mL packages in 50 mL and 100 mL multiple dose vials. Cisplatin is amongst the products in the drug shortage list of USFDA. According to IMS data, the US market for generic Cisplatin is approximately $10 million.
Cisplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly. Cisplatin is a chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1517.90 |
| Dr. Reddys Lab | 6362.00 |
| Cipla | 1478.90 |
| Zydus Lifesciences | 1066.95 |
| Lupin | 1614.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
